TOKYO, Jan 18, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers …
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
LONDON AND HONG KONG, Jan 11, 2023 – (ACN Newswire via SEAPRWire.com) – Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, …
Alercell Is All Set to Launch a Leukemia Diagnostic Test Lena Q51(R)
Bozeman, MT, December 29, 2022 – (SEAPRWire) – Alercell is all set to launch LENA Q51(R) in January 2023. A leukemia diagnostic test based on sequencing DNA will detect …
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics
HONG KONG, Dec 16, 2022 – (ACN Newswire via SEAPRWire.com) – Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic …
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
TOKYO, Dec 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed …
Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront
HONG KONG, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, …
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
TOKYO, Sep 12, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, …
Potential New Therapeutic Approach for Pancreatic Cancer is proposed at 2022 Keystone Meeting: Blocking Obesity or Fatty Acid Oxidation
Seoul, Korea, September 08, 2022 – (SEAPRWire) – In “the immunometabolism at the crossroads of obesity and cancer, Keystone Symposia (Sept. 5-9, 2022, Keystone, Co, USA)”, Dr. Soo-Youl …
New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82%
HANGZHOU, Aug 19, 2022 – (ACN Newswire via SEAPRWire.com) – New Horizon Health (6606.HK), China’s leading biotechnology company for early cancer screening, announced its half-year …